Dr Richard Day

Photo

Personal Profile

Name: Richard Day Email: r.m.day@ucl.ac.uk
Title: Dr Tel: (+44)20 3108 2183
Department: Internal Medicine Fax:
Position: Senior Lecturer Address: Rockefeller Building, 21 University Street, London, WC1E 6JJ
Research Domain: Basic Life Sciences, Experimental Medicine, Infection, Immunology & Inflammation, Materials, Neuroscience, Personalised Medicine, Stem Cells & Regenerative Medicine (Frontier Disciplines) Web Page: Personal Web Page

Profile

Research Description

I lead the UCL Applied Biomedical Engineering Group, based in Division of Medicine. The group is affiliated to the Research Department of Metabolism & Experimental Therapeutics and forms part of the Centre for Cardiovascular Biology and Medicine.


My research interests are centered on the application of biomedical engineering to provide healthcare solutions for debilitating conditions, which contribute to the UCL Grand Challenge of Human Wellbeing. To enable this, we have cross-disciplinary research collaborations with other UCL groups in the Faculties of Engineering, Life Sciences, Mathematical & Physical Sciences, and Medical Sciences, as well as clinical and surgical collaborations at the affiliated University College London Hospital. The group works closely with the UCL Translational Research Office and UCL Business to facilitate clinical translation and commercialization of our exciting and innovative technology.


For more information visit our website: http://www.ucl.ac.uk/day-lab


Research Activities

Biomedical engineering

Development of Rapid Prototypes for Muscle Augmentation Using Magnetic Augmentation

Development of novel stem cell-based therapies for aganglionic gut disorders

Gastrointestinal Regenerative Medicine

Novel therapies for gut disorders/diseases

Education Description

I lead the Tissue Engineering Module (MECHGB07) on the MSc in Biomaterials & Tissue Engineering run by UCL Department of Mechanical Engineering (http://www.mecheng.ucl.ac.uk/learning/graduate/msc/biomaterials-tissue-engineering/).

I also teach on Allergy, Autoimmunity & Transplantation courses (INIM3006 and PATHG014) in the Division of Infection and Immunity, and on MSc/MEng courses in the Department of Biochemical Engineering.


My teaching interests include developing innovative methods for virtual learning environments that facilitate cross-discipline learning.

UCL Collaborators

Dr Suwan Jayasinghe; Dr Gaetano Burriesci; Prof Quentin Pankhurst; Dr Simon Eaton; Dr Anton Emmanuel; Dr Paolo De Coppi; Dr Steven Howe; Dr Nikhil Thapar; Dr Alan Burns

External Collaborators

Publications

    2013

    • Abou Neel EA, Bozec L, Knowles JC, Syed O, Mudera V, Day R, Hyun JK (2013). Collagen - Emerging collagen based therapies hit the patient. Advanced Drug Delivery Reviews, 65(4), 429 - 456. doi:10.1016/j.addr.2012.08.010
    • Ghanbar H, Luo CJ, Bakhshi P, Day R, Edirisinghe M (2013). Preparation of porous microsphere-scaffolds by electrohydrodynamic forming and thermally induced phase separation. MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 33(5), 2488 - 2498. doi:10.1016/j.msec.2012.12.098
    • Riegler J, Liew A, Hynes S, Ortega D, O'Brien T, Day R, Richards T, Sharif F, Pankhurst Q, Lythgoe M (2013). Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials, 34(8), 1987 - 1994.

    2012

    • Gonzalez-Molina J, Riegler J, Southern P, Ortega D, Frangos C, Angelopoulos Y, Husain S, Lythgoe M, Pankhurst Q, Day R (2012). Rapid Magnetic Cell Delivery for Large Tubular Bioengineered Constructs. Journal of the Royal Society Interface, 9(76), 3008 - 3016. doi:10.1098/​rsif.2012.0316
    • Rasekh M, Ahmad Z, Frangos C, Bozec L, Edirisinghe M, Day R (2012). Spatial and Temporal Evaluation of Cell Attachment to Printed Polycaprolactone Microfibers. Acta Biomaterialia, 9(2), 5052 - 5062.

    2011

    • Rasekh M, Ahmad Z, Day R, Edirisinghe M (2011). Printing of Biocompatible Polymers and their Composites for Biomedical Engineering.
    • Rasekh M, Ahmad Z, Day R, Wickham A, Edirisinghe M (2011). Direct Writing of Polycaprolactone Polymer for Potential Biomedical Engineering Applications. Advanced Biomaterials, 13(9), B296 - B305.
    • Ahmadi R, Mordan N, Forbes A, Day RM (2011). Enhanced attachment, growth and migration of smooth muscle cells on microcarriers produced using thermally induced phase separation.. Acta Biomater, 7(4), 1542 - 1549. doi:10.1016/j.actbio.2010.12.022
    • Day RM (2011). Functional Requirements of Wound Repair Biomaterials. In Farrar D (Ed.), Advanced Wound Repair Therapies (pp. 155 - 169). : Woodhead Publishing.

    2010

    • Keshaw H, Foong KS, Forbes A, Day RM (2010). Perianal Fistulae in Crohn’s Disease: Current and Future Approaches to Treatment. Inflammatory Bowel Diseases, 16(5), 870 - 880.
    • Foong KS, Patel R, Forbes A, Day RM (2010). Anti-TNF-alpha-Loaded Microspheres as a Prospective Novel Treatment for Crohn's Disease Fistulae. Tissue Engineering, 16(5), 855 - 864. doi:10.1089/ten.tec.2009.0599
    • Day R (2010). Microspheres.
    • Day R (2010). Porous microspheres and their use in therapy.
    • Keshaw H, Thapar N, Burns AJ, Knowles J, Forbes A, Day RM (2010). Microporous collagen spheres produced via thermally induced phase separation for tissue regeneration. Acta Biomaterialia, 6(3), 1158 - 1166. doi:10.1016/j.actbio.2009.08.044
    • Day RM (2010). Alimentary Tract. In Attala A, Lanza R, Thomson J, Nerem R (Ed.), Principles of Regenerative Medicine (pp. 925 - 941). : Academic Press. doi:10.1016/B978-0-12-381422-7.10050-1

    2009

    • Keshaw H, Georgiou G, Blaker JJ, Forbes A, Knowles JC, Day RM (2009). Assessment of Polymer/Bioactive Glass-Composite Microporous Spheres for Tissue Regeneration Applications. Tissue Engineering: Part A, 15(7), 1451 - 1461. doi:10.1089/ten.tea.2008.0203
    • Amadi A, Fagbemi A, Kelly P, Mwiya M, Torrente F, Salvestrini C, Day R, Golden M, Eklund E, Freeze H, Murch S (2009). Reduced production of sulfated glycosaminoglyans occurs in Zambian children with kwashiorkor but not marasmus. American Journal of Clinical Nutrition, 89, 592 - 600.
    • Day R, Foong K, Goubareva I, Forbes A (2009). Fabrication and Assessment of Microspheres Loaded with Anti-TNF alpha as a Prospective Novel Treatment for Crohn's Disease Fistulae.
    • Moosvi SR, Day R (2009). Bioactive glass modulation of intestinal epithelial cell restitution. Acta Biomaterialia, 5(1), 76 - 83.
    • Day R (2009). Microspheres.
    • Amadi B, Fagbemi AO, Kelly P, Mwiya M, Torrente F, Salvestrini C, Day R, Golden MH, Eklund EA, Freeze HH, Murch SH (2009). Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus. AMERICAN JOURNAL OF CLINICAL NUTRITION, 89(2), 592 - 600. doi:10.3945/ajcn.2008.27092

    2008

    • Day RM, Blaker J (2008). Porous Microspheres and Their Use in Therapy.
    • Moosvi SR, Day RM (2008). Bioactive glass stimulates intestinal epithelial cell restitution.
    • Blaker JJ, Pratten J, Ready D, Knowles JC, Forbes A, Day RM (2008). Assessment of antimicrobial microspheres as a prospective novel treatment targeted towards the repair of perianal fistulae. Aliment.Pharmacol.Ther., 28(5), 614 - 622.
    • Day R (2008). Biomaterials for Gastrointestinal Medicine, Repair and Reconstruction.. In Chu PK, Liu X (Ed.), Biomaterials Fabrication and Processing Handbook (pp. 633 - 658). : CRC Press.
    • Blaker JJ, Knowles JC, Day RM (2008). Novel fabrication techniques to produce microspheres by thermally induced phase separation for tissue engineering and drug delivery. Acta Biomater., 4(2), 264 - 272. doi:10.1016/j.actbio.2007.09.011

    2007

    • Vega R, Keshaw H, Domenech E, Ojanguren II, Gassull MA, Forbes A, Day R (2007). Cytomegalovirus blocks apoptosis in patients with active ulcerative colitis and colonic viral infection.

    2006

    • Keshaw H, Sibbons PD, Forbes A, Day RM (2006). Development of a collagen-ceramic composite for fistula repair.
    • Principi M, Day R, Marangi S, Burattini O, De F, V I, M P, A P, C F, A D, Leo A F, A I, E (2006). Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol.Immunotoxicol., 28(2), 185 - 195.
    • Keshaw H, Forbes A, Day R (2006). Bioactive glass stimulates epithelial wound healing.
    • Keshaw H, Sibbons P, Forbes A, Day R (2006). Development of a collagen-ceramic composite for fistula repair.
    • Day R (2006). Bioactive material for use in stimulating vascularization.
    • Day RM (2006). Epithelial stem cells and tissue engineered intestine. Curr.Stem Cell Res.Ther., 1(1), 113 - 120.
    • Harbord MW, Marks DJ, Forbes A, Bloom SL, Day RM, Segal AW (2006). Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment.Pharmacol.Ther., 24(4), 651 - 660.
    • Polymeros D, Bogdanos D, Day R, Arioli D, Vergani D, Forbes A (2006). Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology, 131(1), 85 - 96. doi:10.1053/j.gastro.2006.04.021
    • Keshaw H, Sibbons PD, Forbes A, Day RM (2006). Development of a collagen-ceramic composite for fistula repair. Gut, 55, A86 - A87.

    2005

    • Day R (2005). Bioactive material for use in stimulating vascularization.
    • Day RM, Boccaccini AR (2005). Effect of particulate bioactive glasses on human macrophages and monocytes in vitro. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 73A(1), 73 - 79. doi:10.1002/jbm.a.30262
    • Boccaccini AR, Blaker JJ, Maquet V, Day RM, Jerome R (2005). Preparation and characterisation of poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass((R)) composite tubular foam scaffolds for tissue engineering applications. Materials Science and Engineering: C, 25(1), 23 - 31.
    • Day RM, Boccaccini A (2005). Effect of Particulate Bioactive Glasses on Human Macrophages In Vitro. J.Biomed.Mat.Res.Pt A, 73(1), 73 - 79.
    • Day RM (2005). Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. Tissue Engineering, 11(5-6), 768 - 777. doi:10.1089/ten.2005.11.768
    • Keshaw H, Forbes A, Day RM (2005). Release of angiogenic growth factors from cells encapsulated in alginate beads with bioactive glass. Biomaterials, 26(19), 4171 - 4179. doi:10.1016/j.biomaterials.2004.10.021
    • Day RM, Maquet V, Boccaccini AR, Jerome R, Forbes A (2005). In vitro and in vivo analysis of macroporous biodegradable poly(D,L-lactide-co-glycolide) scaffolds containing bioactive glass. J.Biomed.Mater.Res.A, 75(4), 778 - 787. doi:10.1002/jbm.a.30433
    • Boccaccini A, Blaker JJ, Maquet V, Day RM, Jerome R (2005). Preparation and characterization of poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass® composite tubular foam scaffolds for tissue engineering applications. Mat.Sci.Eng.C, 25, 23 - 31.

    2004

    • Day R (2004). Bioactive material for use in stimulating vascularization.
    • Day RM, Boccaccini AR, Shurey S, Roether JA, Forbes A, Hench LL, Gabe SM (2004). Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials, 25(27), 5857 - 5866. doi:10.1016/j.biomaterials.2004.01.043
    • Day RM (2004). Bioactive Material for Use in Stimulating Vascularization.
    • Gabe S, Day R, Boccaccini A (2004). Tissue Engineering of the Intestine.. In Wnek GE, Bowlin GL (Ed.), Encyclopedia of Biomaterials and Biomedical Engineering (pp. - ). : Informa Healthcare.
    • Blaker J, Day R, Maquet V, Boccaccini A (2004). Novel bioresorbable poly(lactide-co-glycolide) (PLGA) and PLGA/Bioglass® composite tubular foam scaffolds for tissue engineering applications. Mat.Sci.Forum, 455, 415 - 419.
    • Shetty A, Forbes A, Day RM (2004). Does heparin restore epithelial gag expression in inflammatory bowel disease?.
    • Day RM, Boccaccini AR, Maquet V, Shurey S, Forbes A, Gabe SM, Jerome R (2004). In vivo characterisation of a novel bioresorbable poly(lactide-co-glycolide) tubular foam scaffold for tissue engineering applications. J.Mater.Sci.Mater.Med., 15(6), 729 - 734.

    2003

    • Day RM, Mitchell TJ, Knight SC, Forbes A (2003). Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine, 21(5), 224 - 233.
    • Harbord M, Hankin A, Day R, Bloom SL (2003). Association between p47(phox) pseudogenes and inflammatory bowel disease.
    • Hench LL, Boccaccini AR, Day RM, Gabe SM (2003). Third-generation gene-activating biomaterials. Thermec'2003, Pts 1-5, 426-4, 179 - 184.

    2002

    • Harbord M, Day R, Hankin A, Bloom S, Forbes A, Segal A (2002). Neutrophil respiratory burst and tissue penetration are normal in Crohn’s disease during G-CSF administration.
    • Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH (2002). Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol.Psychiatry, 7(4), 375 - 82, 334.
    • Harbord M, Day R, Hankin A, Bloom S, Forbes A, Segal AW (2002). Neutrophil respiratory burst and tissue penetration are normal in CD during G-CSF administration. GUT, 50, A67 - A67.
    • Day R, Boccaccini AR, Roether JA, Surey S, Forbes A, Hench LL, Gabe S (2002). The effect of Bioglass((R)) on epithelial cell and fibroblast proliferation and incorporation into a PGA matrix. GASTROENTEROLOGY, 122(4), A373 - A373.
    • Day R, Boccaccini A, Roether J, Forbes A, Hench L, Gabe S (2002). The effect of Bioglass® on epithelial cell and fibroblast proliferation and incorporation into a PGA matrix.
    • Day R, Harbord M, Segal A, Forbes A (2002). Differences in micro-vascular blood flow at sites of skin blistering may account for reduced leukocyte trafficking in Crohn's disease. GUT, 50, A77 - A77.
    • Day R, Harbord M, Segal A, Forbes A (2002). Differences in micro-vascular blood flow at sites of skin blisters may account for reduced leukocyte trafficking in Crohn’s disease.

    2001

    • Day RM, Harbord M, Forbes A, Segal AW (2001). Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. Journal of Immunological Methods, 257(1-2), 213 - 220. doi:10.1016/S0022-1759(01)00467-7
    • Harbord M, Day R, Bloom S, Knight S, Forbes A, Segal AW (2001). Neutrophil deficiency during acute inflammation in inflammatory bowel disease. GUT, 48, A20 - A20.
    • Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH (2001). Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. The Journal of Pediatrics, 138(3), 366 - 372.
    • Harbord M, Day R, Bloom S, Knight S, Forbes A, Segal A (2001). Neutrophil deficiency during acute inflammation in inflammatory bowel disease.

    2000

    • Day R, Mitchell T, Knight S, Forbes A (2000). Suppression of epithelial syndecan-1 expression by tumor necrosis factor-A.. GASTROENTEROLOGY, 118(4), A806 - A806.
    • Westphal V, Murch SH, Soohyun K, Greetha S, Winchester B, Day R, Freeze HH (2000). Reduced heparan sulphate accumulaton in enterocytes contributes to protein losing enteropathy in a congenital disorder of glycosylation. American Journal of Pathology, 157, 1917 - 1925.
    • Day R, Mitchell T, Knight S, Forbes A (2000). Suppression of epithelial syndecan-1 expression by tumour necrosis factor alpha.

    1999

    • Day R, Forbes A (1999). Serum basic fibroblast growth factor in inflammatory bowel disease (IBD). GASTROENTEROLOGY, 116(4), A599 - A599.
    • Day R, Forbes A, Talbot I (1999). Expression of the tri-molecular BFGF binding complex in inflammatory bowel disease (IBD). GASTROENTEROLOGY, 116(4), A874 - A874.
    • Day R, Forbes A (1999). Serum basic fibroblast growth factor in inflammatory bowel disease (IBD). GUT, 44(2), 296 - 297.
    • Day R, Talbot I, Forbes A (1999). Expression of the tri-molecular bFGF binding complex in inflammatory bowel disease (IBD). GUT, 44(2), 296 - 296.
    • Day R, Forbes A (1999). Serum basic fibroblast growth factor in inflammatory bowel disease.
    • Day R, Forbes A (1999). Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet, 354(9172), 62 - 65.
    • Day RM, Hao X, Ilyas M, Daszak P, Talbot IC, Forbes A (1999). Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch., 434(2), 121 - 125.
    • Day R, Talbot I, Forbes A (1999). Expression of the tri-molecular bFGF binding complex in inflammatory bowel disease.
    • Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1999). Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig.Dis.Sci., 44(12), 2508 - 2515.

    1998

    • Day R, Forbes A (1998). Induced expression of syndecan-1 in reparative epithelium in vitro.. GASTROENTEROLOGY, 114(4), A960 - A960. doi:10.1016/S0016-5085(98)83912-7
    • Day R, Forbes A (1998). Loss of heparan sulphate-mediated basic fibroblast growth factor (BFGF) binding is restored by heparin. GUT, 42, A46 - A46.
    • Day R, Forbes A (1998). Loss of heparan sulfate mediated basic fibroblast growth factor (bFGF) binding is restored by heparin.. GASTROENTEROLOGY, 114(4), A960 - A960. doi:10.1016/S0016-5085(98)83912-7
    • Day R, Forbes A (1998). Induced expression of syndecan-1 in reparative epithelium in vitro. GUT, 42, A46 - A46.
    • Day R, Forbes A (1998). Induced expression of syndecan-1 in reparative epithelium in vitro.
    • Day R, Forbes A (1998). Loss of heparan sulfate mediated basic fibroblast growth (bFGF) binding is restored by heparin.

    1997

    • Day R, Hao XP, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Changes in syndecan-1 immunoreactivity in the colorectal adenoma-carcinoma sequence.
    • Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism for heparin therapy.
    • Day R, Daszak P, Forbes A (1997). Assessment of tight junction damage by inflammatory modulators using a model for junctional permeability studies. GASTROENTEROLOGY, 112(4), A358 - A358.
    • Day R, Hao XP, Ilyas M, Daszak P, Talbot IC, Forbes A (1997). Changes in syndecan-1 immunoreactivity in the colorectal adenoma-carcinoma sequence.. GASTROENTEROLOGY, 112(4), A553 - A553.
    • Day R, Ilyas M, Daszak P, Talbot I, Forbes A (1997). Expression of syndecan-1 and E-cadherin in inflammatory bowel disease.
    • Day R, Ilyas M, Daszak P, Talbot IC, Forbes A (1997). Expression of syndecan-1 and E-cadherin in inflammatory bowel disease.. GASTROENTEROLOGY, 112(4), A955 - A955.
    • Day R, Forbes A (1997). Soluble E-cadherin measured by enzyme immunoassay in inflammatory bowel disease: a marker of disease activity and epithelial restitution?.
    • Day R, Daszak P, Forbes A (1997). Assessment of tight junction damage by inflammatory modulators using a model for junctional permeability studies.

    1996

    • Day R, Daszak P, Forbes A (1996). Differential ultrastructural changes in cultured HRT-18 cells after treatment with mesalamine and diclofenac.
    • Day R, Daszak P, Forbes A (1996). Differential ultrastructural changes in cultured HRT-18 cells after treatment with mesalamine and diclofenac.. GASTROENTEROLOGY, 110(4), A892 - A892.

    1995

    • ABBASI A, DAY R, TALBOT I, FORBES A (1995). EXPRESSION OF CD4V6 AND 17-1A IN DEVELOPMENT AND PROGNOSIS OF COLORECTAL-CANCER. GASTROENTEROLOGY, 108(4), A443 - A443.
    • ABBASI A, DAY R, TALBOT I, MCKEEGAN E, FORBES A (1995). EXPRESSION OF CADHERINS (E AND P), CATENINS (ALPHA AND BETA) AND DESMOSOME IN NORMAL HUMAN COLORECTAL MUCOSA AND IN COLORECTAL TUMORS. GASTROENTEROLOGY, 108(4), A443 - A443.
    • Abbasi A, Day R, Talbot I, Forbes A (1995). Expression of CD44v6 and 17-1A in development and prognosis of colorectal cancer.
    • Abbasi A, Day R, Talbot I, McKeegan E, Forbes A (1995). Expression of cadherins (E & P), catenins ( & ) and desmosome in normal human colorectal mucosa and in colorectal tumours.

    • Abou Neel EA, Bozec L, Knowles JC, Syed O, Mudera V, Day R, Hyun JK (). Collagen - Emerging Collagen Based Therapies Hit the Patient. Advanced Drug Delivery Reviews, , - .
    • Riegler J, Liew A, Hynes S, Ortega D, O’Brien T, Day R, Richards T, Sharif F, Pankhurst Q, Lythgoe M (). Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials, , - .
    • Day R (). Magnetic Actuation Device.